Karin Jooss's most recent trade in Fate Therapeutics Inc was a trade of 55,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | Karin Jooss | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Karin Jooss | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | Karin Jooss | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 235,000 | 235,000 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | Karin Jooss | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 27,128 | 697,275 (1%) | 0% | 0 | Common Stock | |
| Gritstone Bio Inc | Karin Jooss | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 0.75 per share. | 15 May 2024 | 13,749 | 683,526 (1%) | 0% | 0.7 | 10,288 | Common Stock |
| Gritstone Bio Inc | Jooss Karin | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 235,000 | 235,000 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | Jooss Karin | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 40,000 | 648,851 (1%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Karin Jooss | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | Karin Jooss | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 252,763 | 630,147 (1%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Karin Jooss | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,893 | 11,893 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Karin Jooss | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,650 | 9,848 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Karin Jooss | Director | Sale of securities on an exchange or to another person at price $ 22.82 per share. | 03 Jun 2022 | 1,483 | 1,198 (0%) | 0% | 22.8 | 33,842 | Common Stock |
| Gritstone Bio Inc | Karin Jooss | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 165,600 | 165,600 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | Karin Jooss | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 27,600 | 377,384 (1%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Karin Jooss | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,334 | 4,334 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Karin Jooss | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,681 | 2,681 (0%) | 0% | 0 | Common Stock | |
| Gritstone Bio Inc | Karin Jooss | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | Karin Jooss | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 27,900 | 349,784 (0%) | 0% | 0 | Common Stock |